$395.93
+6.16
(+1.58%)▲
Insights on Medpace Holdings, Inc.
Revenue is up for the last 16 quarters, 204.99M → 511.04M (in $), with an average increase of 5.9% per quarter
Netprofit is up for the last 4 quarters, 61.06M → 102.59M (in $), with an average increase of 15.7% per quarter
1.78%
Downside
Day's Volatility :2.09%
Upside
0.31%
52.19%
Downside
52 Weeks Volatility :55.04%
Upside
5.95%
Period | Medpace Holdings, Inc. | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | 30.73% | 0.5% | 0.0% |
6 Months | 52.33% | 11.7% | 0.0% |
1 Year | 91.13% | 6.2% | 2.2% |
3 Years | 100.6% | 13.5% | -23.0% |
Market Capitalization | 12.0B |
Book Value | $21.72 |
Earnings Per Share (EPS) | 9.82 |
PE Ratio | 39.3 |
PEG Ratio | 2.68 |
Wall Street Target Price | 448.6 |
Profit Margin | 15.92% |
Operating Margin TTM | 20.36% |
Return On Assets TTM | 13.89% |
Return On Equity TTM | 61.35% |
Revenue TTM | 2.0B |
Revenue Per Share TTM | 63.98 |
Quarterly Revenue Growth YOY | 17.7% |
Gross Profit TTM | 925.1M |
EBITDA | 382.1M |
Diluted Eps TTM | 9.82 |
Quarterly Earnings Growth YOY | 0.41 |
EPS Estimate Current Year | 11.21 |
EPS Estimate Next Year | 13.09 |
EPS Estimate Current Quarter | 2.46 |
EPS Estimate Next Quarter | 2.53 |
What analysts predicted
Upside of 13.3%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 704.6M | ↑ 61.55% |
Net Income | 73.2M | ↑ 87.07% |
Net Profit Margin | 10.39% | ↑ 1.42% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 861.0M | ↑ 22.19% |
Net Income | 100.4M | ↑ 37.25% |
Net Profit Margin | 11.67% | ↑ 1.28% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 925.9M | ↑ 7.54% |
Net Income | 145.4M | ↑ 44.74% |
Net Profit Margin | 15.7% | ↑ 4.03% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 1.1B | ↑ 23.38% |
Net Income | 181.8M | ↑ 25.08% |
Net Profit Margin | 15.92% | ↑ 0.22% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 1.5B | ↑ 27.8% |
Net Income | 245.4M | ↑ 34.93% |
Net Profit Margin | 16.81% | ↑ 0.89% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 1.9B | ↑ 29.17% |
Net Income | 282.8M | ↑ 15.26% |
Net Profit Margin | 15.0% | ↓ 1.81% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 394.1M | ↑ 2.7% |
Net Income | 68.7M | ↑ 4.07% |
Net Profit Margin | 17.42% | ↑ 0.23% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 434.1M | ↑ 10.14% |
Net Income | 72.9M | ↑ 6.15% |
Net Profit Margin | 16.79% | ↓ 0.63% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 460.9M | ↑ 6.17% |
Net Income | 61.1M | ↓ 16.22% |
Net Profit Margin | 13.25% | ↓ 3.54% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 492.5M | ↑ 6.86% |
Net Income | 70.6M | ↑ 15.53% |
Net Profit Margin | 14.32% | ↑ 1.07% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 498.4M | ↑ 1.2% |
Net Income | 78.3M | ↑ 10.98% |
Net Profit Margin | 15.71% | ↑ 1.39% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 511.0M | ↑ 2.54% |
Net Income | 102.6M | ↑ 31.03% |
Net Profit Margin | 20.07% | ↑ 4.36% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 967.9M | ↑ 1.81% |
Total Liabilities | 378.2M | ↓ 15.42% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 1.1B | ↑ 18.09% |
Total Liabilities | 416.8M | ↑ 10.19% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 1.4B | ↑ 21.66% |
Total Liabilities | 584.9M | ↑ 40.33% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 1.7B | ↑ 19.36% |
Total Liabilities | 707.0M | ↑ 20.88% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 1.4B | ↓ 18.52% |
Total Liabilities | 966.1M | ↑ 36.65% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 1.7B | ↑ 22.5% |
Total Liabilities | 1.1B | ↑ 13.64% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 1.4B | ↑ 1.81% |
Total Liabilities | 966.1M | ↓ 1.27% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 1.4B | ↑ 3.2% |
Total Liabilities | 1.0B | ↑ 8.52% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 1.4B | ↑ 0.8% |
Total Liabilities | 1.0B | ↓ 3.11% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 1.5B | ↑ 5.67% |
Total Liabilities | 1.0B | ↓ 0.01% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 1.7B | ↑ 11.44% |
Total Liabilities | 1.1B | ↑ 8.08% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 1.8B | ↑ 8.39% |
Total Liabilities | 1.1B | ↑ 2.4% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 156.6M | ↑ 60.79% |
Investing Cash Flow | -17.0M | ↑ 38.7% |
Financing Cash Flow | -141.6M | ↑ 44.72% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 201.9M | ↑ 28.92% |
Investing Cash Flow | -19.1M | ↑ 12.79% |
Financing Cash Flow | -73.9M | ↓ 47.79% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 258.7M | ↑ 28.14% |
Investing Cash Flow | -31.2M | ↑ 63.05% |
Financing Cash Flow | -82.3M | ↑ 11.32% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 263.3M | ↑ 1.8% |
Investing Cash Flow | -31.4M | ↑ 0.48% |
Financing Cash Flow | -44.5M | ↓ 45.97% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 388.1M | ↑ 47.36% |
Investing Cash Flow | -38.7M | ↑ 23.52% |
Financing Cash Flow | -775.8M | ↑ 1645.16% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 136.7M | ↑ 25.99% |
Investing Cash Flow | -9.2M | ↑ 28.29% |
Financing Cash Flow | -131.1M | ↑ 20.18% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 80.1M | ↓ 41.42% |
Investing Cash Flow | -9.5M | ↑ 3.07% |
Financing Cash Flow | -52.7M | ↓ 59.82% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 82.5M | ↑ 3.05% |
Investing Cash Flow | -8.5M | ↓ 10.9% |
Financing Cash Flow | -82.2M | ↑ 56.05% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 114.4M | ↑ 38.62% |
Investing Cash Flow | -8.7M | ↑ 2.3% |
Financing Cash Flow | -49.3M | ↓ 40.07% |
Sell
Neutral
Buy
Medpace Holdings, Inc. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Medpace Holdings, Inc. | -3.22% | 52.33% | 91.13% | 100.6% | 563.89% |
Idexx Laboratories, Inc. | -7.79% | 23.1% | 1.62% | -12.39% | 110.45% |
Agilent Technologies Inc. | -5.57% | 30.74% | 2.44% | -0.71% | 76.14% |
Thermo Fisher Scientific, Inc. | 0.51% | 29.89% | 7.24% | 15.73% | 109.26% |
Danaher Corp. | -1.07% | 26.91% | 5.73% | -4.77% | 87.73% |
Iqvia Holdings Inc. | -5.55% | 26.87% | 23.16% | 0.24% | 68.7% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Medpace Holdings, Inc. | 39.3 | 39.3 | 2.68 | 11.21 | 0.61 | 0.14 | NA | 21.72 |
Idexx Laboratories, Inc. | 49.03 | 49.03 | 4.75 | 11.13 | 0.81 | 0.23 | NA | 17.88 |
Agilent Technologies Inc. | 32.89 | 32.89 | 2.7 | 5.5 | 0.21 | 0.08 | 0.01 | 21.12 |
Thermo Fisher Scientific, Inc. | 37.35 | 37.35 | 2.81 | 21.53 | 0.13 | 0.05 | 0.0 | 120.87 |
Danaher Corp. | 45.86 | 45.86 | 3.13 | 7.63 | 0.08 | 0.04 | 0.0 | 72.16 |
Iqvia Holdings Inc. | 32.05 | 32.05 | 1.33 | 11.11 | 0.23 | 0.05 | NA | 33.67 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Medpace Holdings, Inc. | Buy | $12.0B | 563.89% | 39.3 | 15.92% |
Idexx Laboratories, Inc. | Buy | $41.1B | 110.45% | 49.03 | 23.08% |
Agilent Technologies Inc. | Buy | $40.8B | 76.14% | 32.89 | 18.35% |
Thermo Fisher Scientific, Inc. | Buy | $220.4B | 109.26% | 37.35 | 13.99% |
Danaher Corp. | Buy | $185.5B | 87.73% | 45.86 | 18.55% |
Iqvia Holdings Inc. | Buy | $42.6B | 68.7% | 32.05 | 9.06% |
Vanguard Group Inc
BlackRock Inc
Wasatch Advisors Inc.
Goldman Sachs Group Inc
Amvescap Plc.
Riverbridge Partners LLC
a therapeutically focused leader in research-based drug development, medpace builds strong strategic partnerships with select sponsors to advance the most efficient and cost-effective path to drug approval. as a full service, global clinical research organization (cro), medpace sees itself as a steward of your drug, leveraging its extensive medical and regulatory expertise to deliver additional input, strategy, and efficiencies to each and every phase of the clinical trial. from custom solutions addressing the needs of small and midsize biotechnology companies to full-service offerings for global pharmaceutical companies, medpace has the breadth, depth, and flexibility to deliver a superior result, specific to your needs, on six continents.
Organization | Medpace Holdings, Inc. |
Employees | 5800 |
CEO | Dr. August James Troendle M.D. |
Industry | Commercial Services |